top of page

28 Feb 2023

Press release

Ambrose Healthcare supports Rare Disease Day

Ambrose Healthcare Ltd (Ambrose Healthcare), a new company formed to address the needs of the global rare disease community, supports Rare Disease Day.


The U.S. NIH recognises some 7,000 rare diseases, [1] affecting around 400 million people globally,[2] for which approximately 600 therapies have been approved to date by the U.S. Food and Drug Administration.[3] As such there is still much to be done to close this gap.


Ambrose Healthcare is a specialist pharmaceutical company established to develop and provide treatments for rare diseases and the unmet medical needs of patients managed in a hospital or specialist care setting.


References:

  1. U.S. National Institutes of Health (rarediseases.info.nih.gov/about)

  2. CamRARE – Cambridge Rare Disease Network (www.camraredisease.org/)

  3. National Organization for Rare Disorders (rarediseases.org/new-study-investigates-the-number-of-available-orphan-products-generics-and-biosimilars/

About Ambrose

Ambrose Healthcare is an award-winning pharmaceutical start-up addressing the global need for rare disease treatments.   

 

With only 5-10% of rare diseases having an FDA-approved treatment, Ambrose is on a mission to get safe and effective therapies onto the market and into the hands of patients quickly and cost-effectively.  

For more information, please contact: 

Adam Michael, Director of Communications

adam.michael@ambrosehc.com +44 7775 881 813

bottom of page